Balance between somatostatin and D2 receptor expression drives TSH-secreting adenoma response to somatostatin analogues and dopastatins

Clinical Endocrinology

Volumn 76, Issue 3, 2012, Pages 407-414

  Gatto, Federico ^a,b   Barbieri, Federica ^c,d   Gatti, Monica ^d   Wurth, Roberto ^d   Schulz, Stefan ^e   Ravetti, Jean Louis ^b,f   Zona, Gianluigi ^c,d   Culler, Michael D ^g   Saveanu, Alexandru ^h   Giusti, Massimo ^a   Minuto, Francesco ^a   Hofland, Leo J ^b   Ferone, Diego ^a,c   Florio, Tullio ^b,d  

^a UNIVERSITY OF GENOA   (Italy)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c Gruppo per Lo Studio e la Cura Dei Tumori Cerebrali   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

^e JENA UNIVERSITY HOSPITAL   (Germany)

^f UNIVERSITY OF GENOA   (Italy)

^g Biomeasure Inc   (United States)

^h CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIM 23A387; BIM 23A760; CABERGOLINE; DOPAMINE 2 RECEPTOR; DOPASTATIN DERIVATIVE; OCTREOTIDE; PEPTIDE HORMONE; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR 1; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 3; SOMATOSTATIN RECEPTOR 5; THYROTROPIN; UNCLASSIFIED DRUG;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CASE REPORT; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYROTROPIN SECRETING ADENOMA;

ADENOMA; ADULT; CELL PROLIFERATION; DOPAMINE; DOPAMINE AGONISTS; DRUG SYNERGISM; ERGOLINES; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; OCTREOTIDE; PITUITARY NEOPLASMS; PROTEIN ISOFORMS; RECEPTORS, DOPAMINE D2; RECEPTORS, SOMATOSTATIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SOMATOSTATIN; THYROTROPIN; THYROXINE; TREATMENT OUTCOME; TRIIODOTHYRONINE; TUMOR CELLS, CULTURED;

EID: 84857027904     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2011.04200.x     Document Type: Article

References (37)

1. Beck-Peccoz, P., Persani, L., Mannavola, D., et al. (2009) Pituitary tumours: TSH-secreting adenomas. Best Practice & Research. Clinical Endocrinology & Metabolism 23, 597-606.
2. Kienitz, T., Quinkler, M., Strasburger, C.J., et al. (2007) Long-term management in five cases of TSH-secreting pituitary adenomas: a single center study and review of the literature. European Journal of Endocrinology 157, 39-46. (Pubitemid 47162564)
3. Beck-Peccoz, P., Brucker-Davis, F., Persani, L., et al. (1996) Thyrotropin-secreting pituitary tumors. Endocrine Reviews 17, 610-638. (Pubitemid 26425259)
4. Socin, H.V., Chanson, P., Delemer, B., et al. (2003) The changing spectrum of TSH-secreting pituitary adenomas: diagnosis and management in 43 patients. European Journal of Endocrinology 148, 433-442. (Pubitemid 36527414)
5. Ferone, D., Gatto, F., Arvigo, M., et al. (2009) The clinical-molecular interface of somatostatin, dopamine and their receptors in pituitary pathophysiology. Journal of Molecular Endocrinology 42, 361-370.
6. Lamberts, S.W., Krenning, E.P., &, Reubi, J.C., (1991) The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocrine Reviews 12, 450-482.
7. Florio, T., Thellung, S., Corsaro, A., et al. (2003) Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenoma cells in vitro. Clinical Endocrinology (Oxford) 59, 115-128. (Pubitemid 36774117)
8. Ren, S.G., Kim, S., Taylor, J., et al. (2003) Suppression of rat and human growth hormone and prolactin secretion by a novel somatostatin/ dopaminergic chimeric ligand. Journal of Clinical Endocrinology and Metabolism 88, 5414-5421. (Pubitemid 37452747)
9. Yoshihara, A., Isozaki, O., Hizuka, N., et al. (2007) Expression of type 5 somatostatin receptor in TSH-secreting pituitary adenomas: a possible marker for predicting long-term response to octreotide therapy. Endocrine Journal 54, 133-138. (Pubitemid 46481681)
10. Gatto, F., Barbieri, F., Castelletti, L., et al. (2011) In vivo and in vitro response to octreotide LAR in a TSH-secreting adenoma: characterization of somatostatin receptor expression and role of subtype 5. Pituitary, 14, 141-147.
11. Horiguchi, K., Yamada, M., Umezawa, R., et al. (2007) Somatostatin receptor subtypes mRNA in TSH-secreting pituitary adenomas: a case showing a dramatic reduction in tumor size during short octreotide treatment. Endocrine Journal 54, 371-378. (Pubitemid 47105423)
12. Sharif, N., Gendron, L., Wowchuk, J., et al. (2007) Coexpression of somatostatin receptor subtype 5 affects internalization and trafficking of somatostatin receptor subtype 2. Endocrinology 148, 2095-2105. (Pubitemid 46997042)
13. de Herder, W.W., Reijs, A.E., Feelders, R.A., et al. (2007) Diagnostic imaging of dopamine receptors in pituitary adenomas. European Journal of Endocrinology 156 (Suppl 1), S53-S56. (Pubitemid 46797844)
14. Pivonello, R., Ferone, D., Lombardi, G., et al. (2007) Novel insights in dopamine receptor physiology. European Journal of Endocrinology 156 (Suppl 1), S13-S21. (Pubitemid 46797839)
15. Hofland, L.J., Feelders, R.A., de Herder, W.W., et al. (2010) Pituitary tumours: the sst/D2 receptors as molecular targets. Molecular and Cellular Endocrinology 326, 89-98.
16. Ferone, D., de Herder, W.W., Pivonello, R., et al. (2008) Correlation of in vitro and in vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy. Journal of Clinical Endocrinology and Metabolism 93, 1412-1417. (Pubitemid 351522738)
17. Saveanu, A., Jaquet, P., Brue, T., et al. (2008) Relevance of coexpression of somatostatin and dopamine D2 receptors in pituitary adenomas. Molecular and Cellular Endocrinology 286, 206-213.
18. Colao, A., Filippella, M., Pivonello, R., et al. (2007) Combined therapy of somatostatin analogues and dopamine agonists in the treatment of pituitary tumours. European Journal of Endocrinology 156 (Suppl 1), S57-S63. (Pubitemid 46797845)
19. Rocheville, M., Lange, D.C., Kumar, U., et al. (2000) Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 288, 154-157. (Pubitemid 30203051)
20. Baragli, A., Alturaihi, H., Watt, H.L., et al. (2007) Heterooligomerization of human dopamine receptor 2 and somatostatin receptor 2 Co-immunoprecipitation and fluorescence resonance energy transfer analysis. Cellular Signalling 19, 2304-2316. (Pubitemid 47361686)
21. Kidd, M., Drozdov, I., Joseph, R., et al. (2008) Differential cytotoxicity of novel somatostatin and dopamine chimeric compounds on bronchopulmonary and small intestinal neuroendocrine tumor cell lines. Cancer 113, 690-700.
22. Florio, T., Barbieri, F., Spaziante, R., et al. (2008) Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study. Endocrine-Related Cancer 15, 583-596. (Pubitemid 351880845)
23. Florio, T., (2008) Molecular mechanisms of the antiproliferative activity of somatostatin receptors (SSTRs) in neuroendocrine tumors. Frontiers in Bioscience 13, 822-840.
24. Ferone, D., Saveanu, A., Culler, M.D., et al. (2007) Novel chimeric somatostatin analogs: facts and perspectives. European Journal of Endocrinology 156 (Suppl 1), S23-S28. (Pubitemid 46797840)
25. Jaquet, P., Gunz, G., Saveanu, A., et al. (2005) BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide. Journal of Endocrinological Investigation 28, 21-27.
26. Saveanu, A., Gunz, G., Guillen, S., et al. (2006) Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas. Neuroendocrinology 83, 258-263. (Pubitemid 44578880)
27. Jaquet, P., Gunz, G., Saveanu, A., et al. (2005) Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy. European Journal of Endocrinology 153, 135-141. (Pubitemid 41030524)
28. Barbieri, F., Bajetto, A., Stumm, R., et al. (2008) Overexpression of stromal cell-derived factor 1 and its receptor CXCR4 induces autocrine/paracrine cell proliferation in human pituitary adenomas. Clinical Cancer Research 14, 5022-5032.
29. Florio, T., Pan, M.G., Newman, B., et al. (1992) Dopaminergic inhibition of DNA synthesis in pituitary tumor cells is associated with phosphotyrosine phosphatase activity. Journal of Biological Chemistry 267, 24169-24172.
30. Reubi, J.C., Waser, B., Cescato, R., et al. (2010) Internalized somatostatin receptor subtype 2 in neuroendocrine tumors of octreotide-treated patients. Journal of Clinical Endocrinology and Metabolism 95, 2343-2350.
31. Takeuchi, Y., &, Fukunaga, K., (2003) Differential subcellular localization of two dopamine D2 receptor isoforms in transfected NG108-15 cells. Journal of Neurochemistry 85, 1064-1074. (Pubitemid 36578638)
32. Chanson, P., Weintraub, B.D., &, Harris, A.G., (1993) Octreotide therapy for thyroid-stimulating hormone-secreting pituitary adenomas. A follow-up of 52 patients. Annals of Internal Medicine 119, 236-240. (Pubitemid 23327625)
33. Tagami, T., Usui, T., Shimatsu, A., et al. (2011) Aberrant expression of thyroid hormone receptor {beta} isoform may cause inappropriate secretion of TSH in a TSH-secreting pituitary adenoma. Journal of Clinical Endocrinology and Metabolism 96, E948-E952.
34. Grant, M., Alturaihi, H., Jaquet, P., et al. (2008) Cell growth inhibition and functioning of human somatostatin receptor type 2 are modulated by receptor heterodimerization. Molecular Endocrinology 22, 2278-2292.
35. Taboada, G.F., Luque, R.M., Neto, L.V., et al. (2008) Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR. European Journal of Endocrinology 158, 295-303. (Pubitemid 351404992)
36. Arvigo, M., Gatto, F., Ruscica, M., et al. (2010) Somatostatin and dopamine receptor interaction in prostate and lung cancer cell lines. Journal of Endocrinology 207, 309-317.
37. Duran-Prado, M., Saveanu, A., Luque, R.M., et al. (2010) A potential inhibitory role for the new truncated variant of somatostatin receptor 5, sst5TMD4, in pituitary adenomas poorly responsive to somatostatin analogs. Journal of Clinical Endocrinology and Metabolism 95, 2497-2502.